Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019005 | 0.89 | MAPT (0.62) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23355487 | 0.88 | MAPT (0.61) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3709870 | 0.88 | MAPT (0.61) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3114683 | 0.87 | MAPT (0.57) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5573222 | 0.86 | MAPT (0.76) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3124993 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3785257 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29129953 | 0.85 | GPR119 (0.54) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3807661 | 0.85 | MAPT (0.64) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1136833 | 0.85 | MAPT (0.64) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | VALO HEALTH, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-112823037-B | Inhibition of deubiquitinase USP25 and USP28 | 瓦洛健康股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20220213118-A1 | UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF | CHASER THERAPEUTICS, INC. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3833441-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112823037-A | Inhibition of deubiquitinase USP25 and USP28 | 瓦洛早期发现股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019180686-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | MAPT 2364/4885LMNA 4452/4885ALDH1A1 2323/4885 |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | USP28, USP25, USP30 | MAPT 3174/4885LMNA 3920/4885ALDH1A1 2030/4885 |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | MAPT 1046/4885LMNA 4062/4885ALDH1A1 1934/4885 |
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | USP28, USP25, USP30 | MAPT 3174/4885LMNA 3920/4885ALDH1A1 2030/4885 |
| US-20220213118-A1 | UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF | USP28, USP25, USP24 | MAPT 395/4885LMNA 3098/4885ALDH1A1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.